Pitfalls in molecular diagnosis in haemato-oncology

Journal of Clinical Pathology

Volumn 64, Issue 4, 2011, Pages 275-278

  Mason, Joanne ^a   Akiki, Susanna ^a   Griffiths, Mike J ^a  

^a BIRMINGHAM CHILDREN S HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; FLT3 LIGAND; JANUS KINASE 2; MESSENGER RNA; RNA;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; DIAGNOSTIC VALUE; DISEASE MARKER; EDITORIAL; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; GENE FUNCTION; GENE FUSION; GENE MUTATION; GENETIC VARIABILITY; HEMATOLOGIC MALIGNANCY; HUMAN; LABORATORY TEST; MINIMAL RESIDUAL DISEASE; MOLECULAR DIAGNOSIS; PATIENT MONITORING; PRIORITY JOURNAL; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; SYSTEMIC MASTOCYTOSIS; TANDEM REPEAT; TISSUE TYPES;

FALSE NEGATIVE REACTIONS; FALSE POSITIVE REACTIONS; HEMATOLOGIC NEOPLASMS; HUMANS; MOLECULAR DIAGNOSTIC TECHNIQUES; NEOPLASM, RESIDUAL; PROGNOSIS;

EID: 79953122117     PISSN: 00219746     EISSN: 14724146     Source Type: Journal    
DOI: 10.1136/jcp.2010.081349     Document Type: Editorial

References (25)

1. Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009;114:937-51.
2. Nagata H, Worobec AS, Oh CK, et al. Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. Proc Natl Acad Sci U S A 1995;92:10560-4.
3. Garcia-Montero AC, Jara-Acevedo M, Teodosio C, et al. KIT mutation in mast cells and other bone marrow haematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients. Blood 2006;108:2366-72. (Pubitemid 44497521)
4. Maric I, Robyn J, Fu W, et al. Detection of c-Kit mutation in peripheral blood vs bone marrow aspirates in patients with systemic mastocytosis: comparison study of pathological and clinical laboratory findings in patients with and without detectable c-Kit mutation in the peripheral blood. Blood 2006;108:3596.
5. Minnucci G, Amicarelli G, Salmoiraghi S, et al. A highly sensitive, rapid and non-PCR based method for the detection of the. JAK2 V617F mutation in chronic myeloproliferative neoplasms [abstract]. Haematologica 2010;95(Suppl 2):166, abs. 0408.
6. Sidon P, El Housni H, Dessars B, et al. The JAK2V617F mutation is detectable at very low level in peripheral blood of healthy donors. Leukemia 2006;20:1622. (Pubitemid 44264108)
7. Kottaridis PD, Gale RE, Frew ME, et al. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood 2001;98:1752-9.
8. Beillard E, Pallisgaard N, van der Velden VH, et al. Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using 'real-time' quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR)a Europe against cancer program. Leukemia 2003;17:2474-86.
9. Wang YL, Lee JW, Cesarman E, et al. Molecular monitoring of chronic myelogenous leukemia: identification of the most suitable internal control gene for real-time quantification of BCR-ABL transcripts. J Mol Diagn 2006;8:231-9. (Pubitemid 43811247)
10. Müller MC, Merx K, Weisser A, et al. Improvement of molecular monitoring of residual disease in leukemias by bedside RNA stabilization. Leukemia 2002;16:2395-9. (Pubitemid 36054373)
11. Thörn I, Olsson-Strömberg U, Ohlsen C, et al. The impact of RNA stabilization on minimal residual disease assessment in chronic myeloid leukemia. Haematologica 2005;90:1471-6. (Pubitemid 41658759)
12. van der Velden VH, Boeckx N, Gonzalez M, et al. Differential stability of control gene and fusion gene transcripts over time may hamper accurate quantification of minimal residual disease - a study within the Europe Against Cancer Program. Leukemia 2004;18:884-6. (Pubitemid 38500215)
13. Grimwade D, Jovanovic JV, Hills RK, et al. Prospective minimal residual disease monitoring to predict relapse of acute promyelocytic leukemia and to direct pre-emptive arsenic trioxide therapy. J Clin Oncol 2009;27:3650-8.
14. Sanz MA, Grimwade D, Tallman MS, et al. Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2009;113:1875-91.
15. Mead AJ, Linch DC, Hills RK, et al. FLT3 tyrosine kinase domain mutations are biologically distinct from and have a significantly more favorable prognosis than FLT3 internal tandem duplications in patients with acute myeloid leukemia. Blood 2007;110:1262-70. (Pubitemid 47281424)
16. Warshawsky I, Mularo F, Hren C, et al. Failure of the Ipsogen MutaScreen kit to detect the JAK2 617V>F mutation in samples with additional rare, MutaScreen kit to detect the JAK2 617V>F mutation in samples with additional rare exon 14 mutations: implications for clinical testing and report of a novel 618C>F mutation in addition to 617V>F. Blood 2010;115:3175-6.
17. Saussele S, Weisser A, Müller MC, et al. Frequent polymorphism in BCR exon b2 identified in BCR-ABL positive and negative individuals using fluorescent hybridization probes. Leukemia 2000;14:2006-10.
18. Langabeer SE, Walker H, Gale RE, et al. Frequency of CBF beta/MYH11 fusion transcripts in patients entered into the U.K. MRC AML trials. the MRC Adult Leukaemia Working Party. Br J Haematol 1997;96:736-9.
19. Hackwell SM, Robinson DO, Harvey JF, et al. Identification of false-positive CBFbeta/MYH11 RTPCR results. Leukemia 1999;13:1617-19. (Pubitemid 29465625)
20. Mason J, Griffiths M. Detection of minimal residual disease in leukaemia by RT-PCR. In: Theophilus D, Rapley R, eds. PCR Mutation Detection Protocols. 2nd edn. Methods Mol Bio 2011;688:269-80.
21. Gabert J, Beillard E, van der Velden VH, et al. Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program. Leukemia 2003;17:2318-57.
22. van der Velden VH, Hochhaus A, Cazzaniga G, et al. Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: principles, approaches, and laboratory aspects. Leukemia 2003;17:1013-34. (Pubitemid 36722231)
23. Cross NC. Standardisation of molecular monitoring for chronic myeloid leukaemia. Best Pract Res Clin Haematol 2009;22:355-65.
24. Foroni L, Gerrard G, Nna E, et al. Technical aspects and clinical applications of measuring BCR-ABL1 transcripts number in chronic myeloid leukemia. Am J Hematol 2009;84:517-22.
25. Foroni L, Wilson G, Gerrard G, et al. Guidelines for the measurement of BCR-ABL1 transcripts in Chronic Myeloid Leukaemia. BJH In press. doi:10.1111/j.1365-2141.2011.08603.x